2021
Impact of tissue heterogeneity correction on Gamma Knife stereotactic radiosurgery of acoustic neuromas.
Peters GW, Tien CJ, Chiang V, Yu J, Hansen JE, Aneja S. Impact of tissue heterogeneity correction on Gamma Knife stereotactic radiosurgery of acoustic neuromas. Journal Of Radiosurgery And SBRT 2021, 7: 207-212. PMID: 33898084, PMCID: PMC8055239.Peer-Reviewed Original Research
2019
Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery
McTyre ER, Soike MH, Farris M, Ayala-Peacock DN, Hepel JT, Page BR, Shen C, Kleinberg L, Contessa JN, Corso C, Chiang V, Henson-Masters A, Cramer CK, Ruiz J, Pasche B, Watabe K, D'Agostino R, Su J, Laxton AW, Tatter SB, Fiveash JB, Ahluwalia M, Kotecha R, Chao ST, Braunstein SE, Attia A, Chung C, Chan MD. Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery. Radiotherapy And Oncology 2019, 142: 168-174. PMID: 31526671, DOI: 10.1016/j.radonc.2019.08.011.Peer-Reviewed Original ResearchConceptsBrain metastasis velocityDistant brain failureMedian overall survivalOverall survivalBrain metastasesPredictors of OSInitial brain metastasesNew brain metastasesWhole brain radiationKaplan-Meier methodHigh-risk groupPredictors of outcomeProportional hazards methodsMulti-institutional settingMulti-institutional validationMultivariate regression modelingInitial SRSBrain radiationSalvage modalityInitial treatmentBrain failureRecurrence rateValidation cohortBMV groupMelanoma histologyRADI-31. MULTI-INSTITUTIONAL VALIDATION OF BRAIN METASTASIS VELOCITY, A RECENTLY DEFINED PREDICTOR OF OUTCOMES FOLLOWING STEREOTACTIC RADIOSURGERY
Chan M, McTyre E, Soike M, Ayala-Peacock D, Hepel J, Page B, Contessa J, Chiang V, Attia A, Braunstein S, Chung C, Ruiz J, Fiveash J, Chao S, Farris M. RADI-31. MULTI-INSTITUTIONAL VALIDATION OF BRAIN METASTASIS VELOCITY, A RECENTLY DEFINED PREDICTOR OF OUTCOMES FOLLOWING STEREOTACTIC RADIOSURGERY. Neuro-Oncology Advances 2019, 1: i28-i28. PMCID: PMC7213264, DOI: 10.1093/noajnl/vdz014.123.Peer-Reviewed Original ResearchBrain metastasis velocityDistant brain failureMedian overall survivalOverall survivalPredictors of OSNew brain metastasesImproved overall survivalWhole brain radiationKaplan-Meier methodHigh-risk groupPredictors of outcomeProportional hazards methodsMulti-institutional settingMulti-institutional validationInitial salvageInitial SRSBrain metastasesBrain radiationSalvage modalityInitial treatmentRecurrence rateValidation cohortBrain failureBMV groupHazards methods
2018
Long-term Quality of Life in Survivors of Brain Metastases: A Roller Coaster of Perspective
Reddy NK, Brown FC, Fogarasi MC, Yu JB, Hess J, Chiang VS. Long-term Quality of Life in Survivors of Brain Metastases: A Roller Coaster of Perspective. Cureus 2018, 10: e2358. PMID: 29805927, PMCID: PMC5963947, DOI: 10.7759/cureus.2358.Peer-Reviewed Original Research
2017
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases
Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: 1069-1077. PMID: 28721890, PMCID: PMC6925531, DOI: 10.1016/j.ijrobp.2017.03.030.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBrain NeoplasmsFemaleGenes, rasHumansImmunotherapyLinear ModelsMaleMelanomaMiddle AgedMolecular Targeted TherapyMutationPrognosisProportional Hazards ModelsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-kitRetrospective StudiesStatistics, NonparametricTime FactorsConceptsBRAF-negative patientsBRAF-positive patientsBrain metastasesMedian survivalC-kit mutationsMelanoma patientsPrimary diagnosisWhole-brain radiation therapyOverall median survivalMulti-institutional databaseGene mutation statusOverall survivalInitial treatmentMedian timeTreatment patternsClinical parametersBRAF statusPrognostic valueNRAS mutationsRadiation therapyPatientsMutation statusMetastasisC-kitMEK inhibitors
2015
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis
Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis. Journal Of Clinical Oncology 2015, 34: 123-129. PMID: 26438117, PMCID: PMC5070549, DOI: 10.1200/jco.2015.62.0138.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnaplastic Lymphoma KinaseAntineoplastic AgentsBrain NeoplasmsCarbazolesCarcinoma, Non-Small-Cell LungCranial IrradiationCrizotinibDisease-Free SurvivalFemaleFollow-Up StudiesGene RearrangementHumansKaplan-Meier EstimateKarnofsky Performance StatusLung NeoplasmsMaleMiddle AgedMolecular Targeted TherapyNeoplasm StagingPiperidinesPrognosisProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazolesPyridinesPyrimidinesRadiosurgeryReceptor Protein-Tyrosine KinasesRisk AssessmentRisk FactorsSmokingSulfonesConceptsIntracranial progression-free survivalBrain metastasesProgression-free survivalPrognostic factorsLung cancerMedian intracranial progression-free survivalNon-small cell lung cancerTyrosine kinase inhibitor therapyProgressive brain metastasesRefinement of prognosisKarnofsky performance scorePercent of patientsClinical prognostic factorsPopulation of patientsSingle brain metastasisCell lung cancerKinase inhibitor therapyCox proportional hazardsMulti-institutional studyMedian OSExtracranial metastasesImproved survivalInhibitor therapyInitial treatmentMultivariable analysis
2011
A Comprehensive Review of MR Imaging Changes following Radiosurgery to 500 Brain Metastases
Patel TR, McHugh BJ, Bi WL, Minja FJ, Knisely JP, Chiang VL. A Comprehensive Review of MR Imaging Changes following Radiosurgery to 500 Brain Metastases. American Journal Of Neuroradiology 2011, 32: 1885-1892. PMID: 21920854, PMCID: PMC7966021, DOI: 10.3174/ajnr.a2668.Peer-Reviewed Original ResearchConceptsBrain metastasesMedian survivalMetastatic lesionsLesion sizeMost metastatic lesionsMR imaging changesPercent of lesionsInitial treatment volumeSystemic cancer therapyInitial lesion sizeIntracranial metastatic lesionsGK-SRSLesional responsePatient demographicsRadiographic responseInitial treatmentImaging changesMale sexTumor sizeLesion volumeStereotactic radiosurgeryTreatment dosePatientsLesionsRadiosurgery
2010
Radiosurgery alone for 5 or more brain metastases: expert opinion survey.
Knisely JP, Yamamoto M, Gross CP, Castrucci WA, Jokura H, Chiang VL. Radiosurgery alone for 5 or more brain metastases: expert opinion survey. Journal Of Neurosurgery 2010, 113 Suppl: 84-9. PMID: 21121790, DOI: 10.3171/2010.8.gks10999.Peer-Reviewed Original ResearchConceptsKarnofsky Performance Scale scoreBrain metastasesPerformance Scale scoreStereotactic radiosurgeryClinical factorsScale scoreUse of SRSMore brain metastasesOligometastatic brain metastasesInternational Stereotactic Radiosurgery SocietySystemic disease controlFinal study sampleCharacteristics of physiciansMetastasis locationPatient characteristicsInitial treatmentPhysician characteristicsUnivariate analysisMedian numberClinician's approachMetastasisSRS outcomesSan FranciscoMultivariate analysisDisease control